Abstract:Trehalose, a unique nonreducing crystalline disaccharide, is a potential disease-modifying treatment for neurodegenerative diseases associated with protein misfolding and aggregation due to aging, intrinsic mutations, or autophagy dysregulation. This systematic review summarizes the effects of trehalose on its underlying mechanisms in animal models of selected neurodegenerative disorders (tau pathology, synucleinopathy, polyglutamine tract, and motor neuron diseases). All animal studies on neurodegenerative diseases treated with trehalose published in Medline (accessed via EBSCOhost) and Scopus were considered. Of the 2259 studies screened, 29 met the eligibility criteria. According to the SYstematic Review Center for Laboratory Animal Experiment (SYRCLE) risk of bias tool, we reported 22 out of 29 studies with a high risk of bias. The present findings support the purported role of trehalose in autophagic flux and protein refolding. This review identified several other lesser-known pathways, including modifying amyloid precursor protein processing, inhibition of reactive gliosis, the integrity of the blood-brain barrier, activation of growth factors, upregulation of the downstream antioxidant signaling pathway, and protection against mitochondrial defects. The absence of adverse events and improvements in the outcome parameters were observed in some studies, which supports the transition to human clinical trials. It is possible to conclude that trehalose exerts its neuroprotective effects through both direct and indirect pathways. However, heterogeneous methodologies and outcome measures across the studies rendered it impossible to derive a definitive conclusion. Translational studies on trehalose would need to clarify three important questions: 1) bioavailability with oral administration, 2) optimal time window to confer neuroprotective benefits, and 3) optimal dosage to confer neuroprotection.

Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson’s Disease

Trehalose Inhibits A53T Mutant Α-Synuclein Overexpression and Neurotoxicity in Transduced PC12 Cells.

Trehalose Inhibits Wild-Type Alpha-Synuclein Fibrillation And Overexpression And Protects Against The Protein Neurotoxicity In Transduced Pc12 Cells

Effect of Trehalose on PC12 Cells Overexpressing Wild-Type or A53T Mutant Α-Synuclein

Trehalose Inhibits Fibrillation of A53T Mutant Alpha-Synuclein and Disaggregates Existing Fibrils

Oral Trehalose Intake Modulates the Microbiota–Gut–Brain Axis and Is Neuroprotective in a Synucleinopathy Mouse Model

Trehalose, a Novel Mtor-Independent Autophagy Enhancer, Accelerates the Clearance of Mutant Huntingtin and Α-Synuclein

Alimentary Treatment with Trehalose in a Pharmacological Model of Alzheimer's Disease in Mice: Effects of Different Dosages and Treatment Regimens

Trehalose Attenuates In Vitro Neurotoxicity of 6-Hydroxydopamine by Reducing Oxidative Stress and Activation of MAPK/AMPK Signaling Pathways

Profiling neuroprotective potential of trehalose in animal models of neurodegenerative diseases: a systematic review

Trehalose rescues Alzheimer's disease phenotypes in APP/PS1 transgenic mice.

Trehalose Alleviates PC12 Neuronal Death Mediated by Lipopolysaccharide-Stimulated BV-2 Cells via Inhibiting Nuclear Transcription Factor NF-κB and AP-1 Activation

Trehalose Rescues Alzheimer'S Disease Phenotypes in App/Ps1 Transgenic Mice

Resveratrol alleviates motor and cognitive deficits and neuropathology in the A53T α-synuclein mouse model of Parkinson's disease.

Therapeutic Efficacy Of Aav8-Mediated Intrastriatal Delivery Of Human Cerebral Dopamine Neurotrophic Factor In 6-Ohda-Induced Parkinsonian Rat Models With Different Disease Progression

Autophagic Modulation by Trehalose Reduces Accumulation of TDP-43 in a Cell Model of Amyotrophic Lateral Sclerosis Via TFEB Activation.

Multiple Mechanisms of the Therapeutic Effect of Trehalose in Inhibition of Experimental Neurodegeneration

In vitro modulation of mTOR and mGlur5 influence α-synuclein accumulation

NXP031 prevents dopaminergic neuronal loss and oxidative damage in the AAV-WT-α-synuclein mouse model of Parkinson's disease.

Retinoic Acid Prevents α-Synuclein Preformed Fibrils-Induced Toxicity via Inhibiting STAT1-PARP1 Signaling

Dietary Intake of Α-Ketoglutarate Ameliorates Α-Synuclein Pathology in Mouse Models of Parkinson’s Disease